Printer Friendly

Ichor Medical Systems Forges Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform.

M2 PHARMA-March 28, 2019-Ichor Medical Systems Forges Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform

(C)2019 M2 COMMUNICATIONS

- US-based biotechnology company Ichor Medical Systems, Inc. has entered into a collaboration and research license agreement with AstraZeneca (NYSE: AZN) for the development and clinical assessment of plasmid DNA constructs, the company said.

The plasmids will encode monoclonal antibodies developed by AstraZeneca and will be delivered using Ichor's TriGrid Delivery System.

Under the terms of the agreement, Ichor will receive upfront and annual payments along with development milestones.

The development and optimisation of in vivo expression of DNA-encoded antibodies delivered by the TriGrid is a particularly attractive product strategy in the recombinant monoclonal antibody market.

Utilising this approach, the TriGrid platform works to deliver DNA-encoding monoclonal antibodies directly into a person, after which that person's own cells can begin to manufacture the antibodies.

Ichor's patented TriGrid system uses electroporation, a potent delivery method in which brief electrical pulses are applied to a target tissue to facilitate entry of plasmid DNA into cells, resulting in high expression of genes encoded on the plasmid.

The TriGrid has been utilized in numerous clinical studies of prophylactic and therapeutic DNA vaccines. Improved vaccine potency with TriGrid delivery versus conventional injection, as well as induction of antibody and T cell responses, has been demonstrated in humans.

Ichor Medical Systems' investigational TriGrid Delivery System is the first integrated and fully automated device for electroporation-mediated nucleic acid administration in humans.

Ichor, a privately-held biotech company based in San Diego, CA, is collaborating with partners to provide its enabling TriGrid platform as a means for delivery of nucleic acid-based drugs and vaccines in disease indications such as cancer, hepatitis B virus infection, human papillomavirus infection, and human immunodeficiency virus infection, as well as for multiple biodefense agents.

The TriGrid platform is also being developed for nucleic acid-based antibody delivery as a rapid countermeasure in the event of an infectious disease outbreak or biological weapons attack.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 28, 2019
Words:342
Previous Article:Casma Therapeutics Establishes Scientific Advisory Board with Appointments of Autophagy and Neuroscience Researchers.
Next Article:Can-Fite Releases Mixed Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters